8-K: PROCEPT BioRobotics Reports Strong Fourth Quarter and Full Year 2024 Results, Issues Positive 2025 Guidance

PROCEPT BioRobotics announces a 57% increase in fourth-quarter revenue and issues a promising 2025 revenue guidance of approximately $320 million.

Summary

• PROCEPT BioRobotics reported a total revenue of $68.2 million for Q4 2024, a 57% increase year-over-year.
• U.S. system revenue increased by 67% to $27.6 million in Q4 2024.
• The company sold 60 new robotic systems in the U.S. during the quarter, with an average selling price of approximately $460,000.
• U.S. handpiece and consumables revenue grew by 36% to $29.3 million.
• Full-year 2024 revenue reached $224.5 million, a 65% increase compared to 2023.
• Gross margin for Q4 2024 was 64%, compared to 49% in the prior year period.
• The company reported a net loss of $18.9 million for Q4 2024, an improvement from the $27.5 million loss in the prior year period.
• Adjusted EBITDA loss for Q4 2024 was $10.3 million, compared to a loss of $23.3 million in the prior year period.
• For full year 2024, the net loss was $91.4 million, compared to $105.9 million for the full year 2023.
• Adjusted EBITDA loss for full year 2024 was $61.1 million, compared to a loss of $86.5 million for the full year 2023.
• The company issued 2025 total revenue guidance of approximately $320 million, representing a 42% increase compared to 2024 revenue.
• The company projects revenue for the first quarter of 2025 to be approximately $65.5 million.
• The company projects U.S. system revenue for the first quarter of 2025 to be approximately $18.7 million.
• The company projects U.S. handpieces sold for the first quarter of 2025 to be approximately 10,750.
• The company projects first quarter of 2025 gross margin to be approximately 64%.
• The company projects first quarter of 2025 total operating expense of approximately $71.0 million.
• The company projects full year 2025 gross margin to be approximately 64.5%.
• The company projects full year 2025 total operating expense of approximately $300 million.
• The company projects full year 2025 Adjusted EBITDA loss to be approximately $35 million.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong revenue growth, improved gross margins, and promising guidance for 2025. The FDA clearances and clinical study initiations further contribute to the positive sentiment, despite the reported net losses and EBITDA losses.

Positives

• Significant revenue growth in both Q4 and full-year 2024.
• Strong growth in U.S. system revenue and handpiece sales.
• Improved gross margin in Q4 and full-year 2024.
• Reduced net loss and Adjusted EBITDA loss compared to the previous year.
• Positive revenue guidance for 2025, indicating continued growth.
• FDA clearance for the HYDROS Robotic System.
• FDA-IDE approval to initiate WATER IV PCa clinical study.

Negatives

• The company experienced a net loss for both Q4 and full-year 2024.
• The company experienced an Adjusted EBITDA loss for both Q4 and full-year 2024.
• Operating expenses increased in both Q4 and full-year 2024.
• An acute saline shortage in Q4 2024 impacted handpiece order patterns.

Risks

• The company's forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.
• The company's filings with the Securities and Exchange Commission (the SEC), including the Company's annual report on Form 10-K filed with the SEC on February 28, 2024, and subsequent quarterly reports on Form 10-Q and, when available, the Company's annual report on Form 10-K for the year ended December 31, 2024, describe these risks and uncertainties more fully.
• The company experienced an acute saline shortage in Q4 2024, particularly in November 2024, which impacted handpiece order patterns.

Future Outlook

The company projects revenue for the full year 2025 to be approximately $320 million, representing a 42% increase over the prior year. The company projects full year 2025 Adjusted EBITDA loss to be approximately $35 million.

Management Comments

• Reza Zadno, Chief Executive Officer, stated that 2024 was a productive year for PROCEPT in two key areas: receiving FDA 510(k) clearance of the HYDROS Robotic System and receiving FDA-IDE approval to initiate WATER IV PCa.

Industry Context

PROCEPT BioRobotics operates in the surgical robotics market, specifically focusing on urology and the treatment of BPH. The company's advancements in robotic technology and clinical studies position it to compete effectively in this growing market.

Comparison to Industry Standards

• Intuitive Surgical, a leader in surgical robotics, reported revenue growth of 12% in Q4 2024, while PROCEPT BioRobotics reported revenue growth of 57% for the same period.
• Globus Medical, another player in the surgical robotics space, reported revenue growth of 10% in Q4 2024, while PROCEPT BioRobotics reported revenue growth of 57% for the same period.
• Medtronic, a large medical device company, reported revenue growth of 4.7% in Q4 2024, while PROCEPT BioRobotics reported revenue growth of 57% for the same period.
• These comparisons suggest that PROCEPT BioRobotics is growing at a faster rate than some of its competitors in the surgical robotics market.

Stakeholder Impact

• Shareholders: The positive financial results and future guidance are likely to be viewed favorably by shareholders.
• Employees: The company's growth and expansion may create new job opportunities and career advancement prospects for employees.
• Customers: The company's innovative products and therapies may improve patient outcomes and quality of life for customers.
• Suppliers: The company's increased sales and production may lead to increased demand for suppliers' products and services.
• Creditors: The company's strong financial position and positive outlook may enhance its creditworthiness and access to capital.

Next Steps

• The company will host a conference call to discuss the fourth quarter 2024 financial results on February 25, 2025.
• The company will continue to pursue its long-term growth strategy and focus on profitability.

Key Dates